Abstract
Background
Tc-99m pyrophosphate (PYP) SPECT is recommended for indeterminate findings on planar imaging. We aimed to compare the findings on planar PYP scintigraphy alone to that of routinely performed PYP SPECT.
Methods
PYP scintigraphy data of 133 patients (53% men; mean age 76 years) were evaluated. SPECT was routinely performed following 1-hour planar imaging, in all cases. Semiquantitative visual score and heart-to-contralateral (H/CL) ratio were determined in all patients as recommended.
Results
PYP images from 35 patients (26%) were considered to be positive based on SPECT myocardial uptake. Among them, 20 (57%) had a H/CL ratio ≥1.5 and 34 had a visual score ≥ 2. SPECT identified myocardial uptake in one patient with a visual score < 2 and refuted the presence of myocardial uptake in two patients with a visual score ≥ 2. Visual score correlated well with SPECT (r = 0.94; P < .0001) and had an accuracy of 98% for tomographic myocardial uptake. Addition of H/CL ratio reduced the diagnostic performance of visual score.
Conclusions
Planar-derived visual score has an excellent accuracy for tomographic myocardial uptake, though it misclassifies a small proportion of patients. H/CL ratio decreases the diagnostic certainty of planar imaging. Tomographic imaging prevents misdiagnoses and should always be performed.
Abbreviations
- PYP:
-
Techneticum-99m pyrophosphate
- TTR-CA:
-
Transthyretin cardiac amyloidosis
- H/CL:
-
Heart-to-contralateral
- ASNC:
-
American Society of Nuclear Cardiology
- SPECT:
-
Single photon emission computed tomography
- LVEF:
-
Left ventricular ejection fraction
References
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12.
Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–84.
Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195–201.
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Card Fail. 2019;25:e1–39.
Masri A, Bukhari S, Ahmad S, Nieves R, Eisele YS, Follansbee W, et al. Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis. Circ Cardiovasc Imaging. 2020;13:e010249.
Sperry BW, Burgett E, Bybee KA, McGhie AI, O’Keefe JH, Saeed IM et al. Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT/CT. J Nucl Cardiol 2020.
Asif T, Araujo T, Singh V, Malhotra S. High prevalence of heart failure with reduced ejection fraction in patients with transthyretin cardiac amyloidosis. J Nucl Cardiol. 2020;27:1044–6.
Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med. 1987;147:1039–44.
Wehbe RM, Kansal P, Holly TA. Cases from a busy nuclear cardiology laboratory: Potential pitfalls in the interpretation of cardiac scintigraphy for ATTR cardiac amyloidosis. J Nucl Cardiol. 2020. https://doi.org/10.1007/s12350-020-02094-4.
Dorbala S, Bokhari S, Miller EJ, Bullock-Palmer R, Soman P, Thompson R. 99mTechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. American Society of Nuclear Cardiology Practice Points 2016.
Ramsay SC, Cuscaden C. The current status of quantitative SPECT/CT in the assessment of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2019. https://doi.org/10.1007/s12350-019-01935-1.
Hussain M, Collier P, Jaber W. Value of SPECT imaging in patients with TTR-amyloid: Ratios are not enough. J Nucl Cardiol. 2019. https://doi.org/10.1007/s12350-019-01997-1.
Disclosures
Talal Asif, Javier Gomez-Valencia, Vasvi Singh, Rami Doukky, and Arlet Nedeltcheva have nothing to disclose. Saurabh Malhotra—Speakers Bureau: Pfizer and Akcea Therapeutics, and Advisory Board: Akcea Therapeutics
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarizes the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.
Funding
This study was supported in part by the Becker Fund for Heart Research, Community Foundation of Greater Buffalo.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Asif, T., Gomez, J., Singh, V. et al. Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: Perils and pitfalls. J. Nucl. Cardiol. 28, 104–111 (2021). https://doi.org/10.1007/s12350-020-02328-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12350-020-02328-5